UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.274

Sortiert nach

Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder

Cochrane database of systematic reviews, 2007-10 (4), p.CD005648

2007

Volltextzugriff (PDF)

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder

The American journal of psychiatry, 2015-12, Vol.172 (12), p.1197-1206

2015

Volltextzugriff (PDF)

Dopamine depleters in the treatment of hyperkinetic movement disorders

Expert opinion on pharmacotherapy, 2016-12, Vol.17 (18), p.2461-2470

Jankovic, Joseph

2016

Volltextzugriff (PDF)

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

The Journal of pharmacology and experimental therapeutics, 2010-07, Vol.334 (1), p.171

2010

Volltextzugriff (PDF)

Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with Huntington’s disease: Pharmacokinetic and brain delivery study

Chemistry and physics of lipids, 2020-08, Vol.230, p.104917-104917, Article 104917

2020

Volltextzugriff (PDF)

Pharmacodynamics and metabonomics study of Tianma Gouteng Decoction for treatment of spontaneously hypertensive rats with liver-yang hyperactivity syndrome

Journal of ethnopharmacology, 2020-05, Vol.253, p.112661-112661, Article 112661

2020

Volltextzugriff (PDF)

Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

The Journal of neuroscience, 2013-02, Vol.33 (9), p.3953-3966

2013

Volltextzugriff (PDF)

Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors

Nature neuroscience, 2011-07, Vol.14 (8), p.1033-1038

2011

Volltextzugriff (PDF)

Aripiprazole for autism spectrum disorders (ASD)

Cochrane database of systematic reviews, 2016-06, Vol.2016 (6), p.CD009043

2016

Volltextzugriff (PDF)

Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial

Schizophrenia research, 2014-03, Vol.153 (1), p.169-176

2014

Volltextzugriff (PDF)

Epileptiform activity and cognitive deficits in SNAP-25(+/-) mice are normalized by antiepileptic drugs

Cerebral cortex (New York, N.Y. 1991), 2014-02, Vol.24 (2), p.364-376

2014

Volltextzugriff (PDF)

A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia

Neuropsychopharmacology (New York, N.Y.), 2011-08, Vol.36 (9), p.1903

2011

Volltextzugriff (PDF)

Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature

Clinical therapeutics, 2012-07, Vol.34 (7), p.1487-1504

2012

Volltextzugriff (PDF)

Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M 4 PAM VU0467154

Neuropharmacology, 2018-01, Vol.128, p.492

2018

Volltextzugriff (PDF)

Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine D2 pathways

Molecular psychiatry, 2012-01, Vol.17 (1), p.85-98

2012

Volltextzugriff (PDF)

Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

Neuropsychopharmacology (New York, N.Y.), 2014-06, Vol.39 (7), p.1578-1593

2014

Volltextzugriff (PDF)

Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study

Journal of neurotrauma, 2010-05, Vol.27 (5), p.911

2010

Volltextzugriff (PDF)

Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents

Journal of clinical psychopharmacology, 2022-05, Vol.42 (3), p.238

2022

Volltextzugriff (PDF)

Reversal of morphine conditioned behavior by an anti-dopaminergic post-trial drug treatment during re-consolidation

Behavioural brain research, 2019-02, Vol.359, p.771-782

2019

Volltextzugriff (PDF)

Internet-Based, Randomized, Controlled Trial of Omega-3 Fatty Acids for Hyperactivity in Autism

Journal of the American Academy of Child and Adolescent Psychiatry, 2014-06, Vol.53 (6), p.658-666

2014

Volltextzugriff (PDF)

Structure–Functional Selectivity Relationship Studies of β‑Arrestin-Biased Dopamine D2 Receptor Agonists

Journal of medicinal chemistry, 2012-08, Vol.55 (16), p.7141-7153

2012

Volltextzugriff (PDF)

Effects of the Hyptis martiusii Benth. leaf essential oil and 1,8-cineole (eucalyptol) on the central nervous system of mice

Food and chemical toxicology, 2019-11, Vol.133, p.110802-110802, Article 110802

2019

Volltextzugriff (PDF)

Histamine H3 receptor antagonism modulates autism-like hyperactivity but not repetitive behaviors in BTBR T+Itpr3tf/J inbred mice

Pharmacology, biochemistry and behavior, 2022-01, Vol.212, p.173304-173304, Article 173304

2022

Volltextzugriff (PDF)

Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine

Bipolar disorders, 2015-08, Vol.17 (5), p.507-517

2015

Volltextzugriff (PDF)

Guanabenz Reverses a Key Behavioral Change Caused by Latent Toxoplasmosis in Mice by Reducing Neuroinflammation

mBio, 2019-04, Vol.10 (2)

2019

Volltextzugriff (PDF)

1 – 25 von 1.274

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(992)
Mit Volltextzugriff
(709)

Publikationsform

Artikel
(1.268)
magazinearticle
(6)

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder

Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder

Dopamine depleters in the treatment of hyperkinetic movement disorders

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with Huntington’s disease: Pharmacokinetic and brain delivery study

Pharmacodynamics and metabonomics study of Tianma Gouteng Decoction for treatment of spontaneously hypertensive rats with liver-yang hyperactivity syndrome

Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors

Aripiprazole for autism spectrum disorders (ASD)

Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial

Epileptiform activity and cognitive deficits in SNAP-25(+/-) mice are normalized by antiepileptic drugs

A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia

Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature

Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M 4 PAM VU0467154

Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine D2 pathways

Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study

Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents

Reversal of morphine conditioned behavior by an anti-dopaminergic post-trial drug treatment during re-consolidation

Internet-Based, Randomized, Controlled Trial of Omega-3 Fatty Acids for Hyperactivity in Autism

Structure–Functional Selectivity Relationship Studies of β‑Arrestin-Biased Dopamine D2 Receptor Agonists

Effects of the Hyptis martiusii Benth. leaf essential oil and 1,8-cineole (eucalyptol) on the central nervous system of mice

Histamine H3 receptor antagonism modulates autism-like hyperactivity but not repetitive behaviors in BTBR T+Itpr3tf/J inbred mice

Lithium modulates the production of peripheral and cerebral cytokines in an animal model of mania induced by dextroamphetamine

Guanabenz Reverses a Key Behavioral Change Caused by Latent Toxoplasmosis in Mice by Reducing Neuroinflammation

Suchergebnisse filtern